PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Benlysta

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. What diagnosis is this drug being prescribed for (pick one)?

☐ Active systemic lupus erythematosus (SLE) ☐ Other

Q2. Please provide ICD code(s) for diagnosis:

Q3. Is Benlysta being used in combination with at least one standard SLE therapy (e.g., corticosteriods, hydroxychloroquine, NSAIDs, azathioprine, methotrexate, mycophenolate)?

☐ Yes ☐ No

Q4. Does the patient have documented intolerance, FDA-labeled contraindication, or hypersensitivity to the standard of care drugs listed above?

☐ Yes ☐ No

Q5. Is the prescribing physician a rheumatologist?

☐ Yes ☐ No

Q6. Does the patient have severe active lupus nephritis?

☐ Yes ☐ No

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Benlysta

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

Q7. Does the patient have severe active central nervous system lupus?

☐ Yes ☐ No

Q8. Is Benlysta being used in combination with other biologic therapies (e.g., Actemra, Cimzia, Enbrel, Orencia, Remicade, Rituxan, Simponi, Stelara)?

☐ Yes ☐ No

Q9. Is Benlysta being used in combination with intravenous cyclophosphamide?

☐ Yes ☐ No

Q10. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement?

☐ Pharmacy
☐ Individual prescriber
☐ Provider or specialty group
☐ Facility
☐ Other (please specify)

Q11. Provide name and NPI of the billing entity

Q12. Will the claim for the drug be submitted as a MEDICAL claim or PHARMACY claim (Note: If a pharmacy will be submitting a MEDICAL claim for drug reimbursement, answer MEDICAL)?

☐ Medical ☐ Pharmacy

Q13. Additional comments:

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Benlysta

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**
Prescriber Signature	Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document